Jennifer Lachey - 04 Apr 2022 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Chief Scientific Officer
Signature
/s/ Keith Regnante, Attorney-in-Fact
Issuer symbol
KROS
Transactions as of
04 Apr 2022
Net transactions value
-$474,615
Form type
4
Filing time
06 Apr 2022, 16:49:31 UTC
Previous filing
15 Mar 2022
Next filing
13 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KROS Common Stock Options Exercise $2,385 +7,950 +9.3% $0.3000* 93,650 04 Apr 2022 Direct
transaction KROS Common Stock Sale $477,000 -7,950 -8.5% $60.00 85,700 04 Apr 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS of Shares Employee Stock Option (right to buy) Options Exercise $0 -7,950 -9.4% $0.000000 76,705 04 Apr 2022 Common Stock 7,950 $0.3000 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 Immediately exercisable.